Chiral 3-(4,5-dihydrooxazol-2-yl)phenyl alkylcarbamates as novel FAAH inhibitors: Insight into FAAH enantioselectivity by molecular docking and interaction fields

Research output: Contribution to journalArticleScientificpeer-review

Researchers

  • Mikko J. Myllymaki
  • Heikki Kasnanen
  • Antti O. Kataja
  • Maija Lahtela-Kakkonen
  • Susanna M. Saario
  • Antti Poso
  • Ari Koskinen

Research units

Abstract

Fatty acid amide hydrolase (FAAH) and monoglyceride lipase (MGL) are the main enzymes responsible for the hydrolysis of endogenous cannabinoids N-arachidonoylethanolamide (AEA) and 2-arachidonoylglycerol (2-AG), respectively. Phenyl alkylcarbamates are FAAH inhibitors with anxiolytic and analgesic activities in vivo. Herein we present for the first time the synthesis and biological evaluation of a series of chiral 3-(2-oxazoline)-phenyl N-alkylcarbamates as FAAH inhibitors. Furthermore, the structural background of chirality on the FAAH inhibition is explored by analyzing the protein–ligand interactions. Remarkably, 10-fold difference in potency was observed for (R)- and (S)-derivatives of 3-(5-methyl-4,5-dihydrooxazol-2-yl)phenyl cyclohexylcarbamate (6a vs. 6b). Molecular modelling indicated an important interaction between the oxazoline nitrogen and FAAH active site.

Details

Original languageEnglish
Pages (from-to)4179-4191
JournalEUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
Volume44
Issue number10
Publication statusPublished - 2009
MoE publication typeA1 Journal article-refereed

    Research areas

  • FAAH inhibitor, fatty acid amide hydrolase (FAAH), carbamate, enantiomeric pair

Download statistics

No data available

ID: 2422616